News at CenExel

CenExel Clinical Research Acquires California Neuroscience Research

Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...

Esketamine Receives Support from 2 FDA Committees

Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...

Depression Treatment Gaithersburg

Depression treatment Gaithersburg. If you are experiencing depression and no medications have really helped, maybe one of our trials will.

Depression Research Study Participants Needed

Depression research study participants needed to take part in several clinical research trials exploring the effects of rapastinel, esketamine, and ketamine like compounds. Generally, research participants for these trials should: Be diagnosed with major depression Be...

Translate »